United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$269.78 USD
+5.44 (2.06%)
Updated May 14, 2024 04:00 PM ET
After-Market: $268.29 -1.49 (-0.55%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 581 - 587 ( 587 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Think Q1 Will Be Either In-Line Or Squeak By Consensus--Tyvaso Is The Wild Card.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Uptake Looks Strong - Reiterate Buy.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Response To The Tyvaso MAA Withdrawal, We Are Lowering Our Fair Value to $59 But Maintaining Our NEUTRAL Rating.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Robust Quarter - Reiterating Buy
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Revenues Slightly Beat Our and Consensus Estimates but GAAP EPS Missed on Higher Operating Expenses
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Although We Raised Our Q4 Estimates, Consensus Is Still Relatively High. Even So, We Believe Investors Are Focused On Better Than Expected Product Launches
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L